ISH MATTERS

Colombia and the 2024 ISH meeting: Improving the control of hypertension worldwide

PATRICIO LOPEZ-JARAMILLO DAGNOVAR ARISTIZABAL

Sociedad Colombiana de Cardiología and International Society of Hypertension





Introduction

Cardiovascular disease (CVD) is the leading cause of death globally, accounting for approximately 32% of all deaths, with approximately 33% of which occurred prematurely. Although the prevalence of CVD is rising globally, developing regions have both a higher incidence rate and cardiovascular mortality. In low- and middle-income countries (LICs and MICs) CVDs are contributing to poverty due to catastrophic health expenses borne by patients and premature deaths during their most productive years, with wide-scale effects on the economy.1 Large-scale prospective cohort studies have shown that about 70% of CVD cases can be attributed to a small cluster of individual modifiable risk factors, among which hypertension, high non-high-density lipoprotein (HDL) cholesterol, low education, tobacco use, household air pollution, and poor diet have the biggest population attributable fractions (PAFs).²

Hypertension (HTA) remains as the principal risk factor for CVD worldwide, particularly in LICs and MICs. In a recent study in South American countries³ we have demonstrated that for CVD, largest PAFs were due to hypertension (18.7%), abdominal obesity (15.4%), tobacco use (13.5%), low strength (5.6%), and diabetes (5.3%). For death, the largest PAFs were from tobacco use (14.4%), hypertension (12.0%), low education (10.5%), abdominal obesity (9.7%), and diabetes (5.5%) [figure 1].

Despite of the important contribution of HTA to CVD and mortality, the rates of awareness, treatment and control are so low globally but particularly in LICs and MICs. The PURE study shows that among the 142 042 participants 40.8% had hypertension but only 46.5% were aware of the diagnosis. Of those who were aware of the diagnosis, the majority (87.5%) of those who were aware receiving pharmacological treatments, but only a minority of those receiving treatment were controlled 32.5%. Overall, 30.8% of treated patients were taking 2 or more types of blood pressure-lowering medications. The percentages aware, treated and controlled in LICs were lower in LICs compared with all other countries.

These findings suggest substantial room for improvement in hypertension diagnosis and treatment. This is the reason why in our next meeting of the ISH one of the principal aims will be a deep discussion about the strategies to improve the control of hypertension worldwide. We will have the opportunity to present the results of the MMM initiative in the specific goal of improve hypertension awareness⁵, and how the contribution of clinical trials as HOPE-3⁶, HOPE-4⁷, programs as RESOLVE and HEARTS⁸, and the new guidelines of the ISH⁹ and WHO¹⁰ could be implemented globally to improve the rates of diagnosis, treatment and control of hypertension.






Figure 1. Cardiovascular diseases (CVD) are the leading cause of mortality in South America and hypertension have the largest population attributable fraction for CVD. [Reproduced of reference 3].

The next Congress of the International Society of Hypertension in 2024 will be held in Cartagena, Colombia, one of the most beautiful colonial cities in Latin America. Cartagena has been declared world's heritage site since 1984, due to its amazing architecture and history. Cartagena's ensemble of forts is not only the biggest in South America, but also one of the best preserved; in addition, its coastal location and charming cuisine, has made the city an highly attractive tourist destination. More than one million tourists from around the world visit Cartagena every year.¹¹

It's been a long time since our ISH Congress was in Latin-America. For this come back we have already started our journey to make your visit a memorable scientific and cultural experience. A plural regional organizing committee linked with all cardiovascular and hypertension societies in Latina America will be involved in this undertaking. Scientific societies such as Pan-American Health Organization, World Heart Federation, Latin-American Society of Hypertension and Interamerican Society of Cardiology have endorsed the ISH 2024.









We look forward to seeing all the delegates from around the world, dedicated to research, diagnose and treat high blood pressure in Cartagena. In addition to discuss the best strategies to improve the control of HTA, our ISH 2024 Congress will be focused on four key topics:

- 1. Hypertension care with multidisciplinary teams and standardized processes, we will also explore the application of telemedicine and the new remote patient monitoring techniques and devices.
- 2. Predictive and analytical models of response to non-pharmacological and pharmacological therapies.
- 3. Evaluation and treatment of special populations: elderly, ethnic groups, minorities, frail and multi-morbid patients.
- 4. Applied research and translational medicine: molecular and pathophysiological mechanisms, genetic factors and hypertension in animal models.



In addition, several inter-society symposiums will be held, which will be a great opportunity to interact and make connections with eminent experts and leaders of arterial hypertension from around the world. The fact that the ISH Congress have become such a great gathering to display and discuss the research developments in hypertension has helped everyone to have a better understanding of the rapid changes in in the field and to focus the research efforts accordingly. We, as a part of the Organizing Committee, are certain that the takeaways of the 30th Congress of the ISH will further deepen our understanding to improve the control of hypertension worldwide.

We are sure that Cartagena will love you and we are doing the best to guarantee that your stay in Colombia will be full of science, joy and happiness

References

- 1. World Health Organization [internet]. Cardiovascular diseases (CVDs) Fact sheet; 2021. Available at: https:/www.who.int/ news-room/ fact-sheets/detail/cardiovascular-diseases-(c vds); Cited 2022 November 3.
- 2. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle- income, and low-income countries (PURE): a prospective cohort study. Lancet 2020; 395:795-808
- 3. Lopez-Jaramillo P, Joseph P, Lopez-Lopez JP, et al. Risk factors, cardiovascular disease, and mortality in South America: a PURE substudy. Eur Heart J. 2022; 43:2841-2851.

Patricio Lopez-Jaramillo – jplopezj@gmail.com

Dagnovar Aristizabal – dagnovar@une.net.co

- 4. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310:959-968.
- 5. Poulter NR, Borghi C, Damasceno A, et al. May Measurement Month 2019: results of blood pressure screening from 47 countries. Eur Heart J Suppl. 2021;23(Suppl B):B1-B5.
- 6. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Bloodpressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374: 2009-2020.
- 7. Schwalm JD, McCready T, Lopez-Jaramillo P, et al. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. Lancet. 2019; 394:1231-1242.
- 8. WHO. WHO CVD-risk management package for low- and medium-resource settings. Geneva: World Health Organization, 2002.
- 9. Al-Makki A, DiPette D, Whelton PK, et al Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary. Hypertension. 2022; 79: 293-30.
- 10. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hyper-tension global hypertension practice guidelines. J Hypertens. 2020, 38, 982-1004.
- 11. UNESCO. Port, Fortresses and Group of Monuments, Cartagena. 1984. https://whc.unesco. org/en/list/285. Website, access November 3, 2022.

